Premium
Opportunities to optimise direct‐acting oral anticoagulants
Author(s) -
Thompson Angus
Publication year - 2020
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1874
Subject(s) - edoxaban , rivaroxaban , dabigatran , apixaban , medicine , warfarin , intensive care medicine , atrial fibrillation
The newer direct‐acting oral anticoagulants (DOACs) – apixaban, dabigatran, edoxaban, rivaroxaban – offer many advantages over older anticoagulants such as warfarin. However, in order to optimise their benefits, it is important that patients taking them do not become too blasé, advises Angus Thompson.